Allergan

(AGN) - Get Report

announced Friday that it got FDA approval for its once-daily prescription eye drop Lumigan as a first-line treatment for elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Earlier, Lumigan -- bimatoprost ophthalmic solution 0.03% -- had received approval in 2001 as a pressure-lowering medication for second-line use.

Currently, open-angle glaucoma affects about 3 million people in the United States and is considered the major cause of curable blindness.

This story was created through a joint venture between TheStreet.com and IRIS.